






In my work on the social impacts of new technologies, I have dealt 
with a wide variety of issues related to the new biopesticides. As a 
Peace Corps volunteer in Botswana, I tried to grow vegetables for the 
market in an environment which fairly teemed with all manner of 
pests from caterpillars to elephants. There was little we could do about 
the elephant—but we fought insect pests like the caterpillars with a 
variety of pesticides such as Chlordane and Malathion. And those pes-
ticides worked—they killed the pests, they kept blight off the toma-
toes, and they killed the caterpillars on the cabbages.
But though these insecticides worked, I was uncomfortable using 
them. I read the labels, and did not like the cavalier way in which my 
colleague, a missionary farmer from North Carolina—mixed and ap-
plied them. I also had to wonder about the usefulness of pesticides to 
local people—we were, after all, there to help them. But even though 
the chemicals worked, few people could afford them. Fewer yet could 
read the labels and mix them safely and properly. And there was the 
disturbing tendency for any impermeable container to be used for wa-
ter storage.
The pesticides carried certain benefits, but they also carried certain 
costs. This Janus-like character is true of any new technology. The bal-
ance of costs and benefits is as much a function of the social, economic 
and environmental conditions in which the technology is deployed as 
it is of the characteristics of the technology itself. Even in the advanced
industrial nations, though pesticides did indeed confer benefits, their 
use also entailed substantial costs both to the user and to society as a 
whole.
Ten years ago in Botswana, I was not aware of alternatives to che-
mical pesticides. Today, they are in the headlines of the news. For 
example, there has been the development and the promise of a broad 
range of biopesticides: pheromone traps, engineering cross resistance 
in plants, encoding toxin genes in plants, encoding insecticidal or anti-
viral or anti-fungal genes in rhizobacteria. And biotechnology prom-
ises to greatly facilitate the development of such biopesticides.
BIOTECHNOLOGY UTOPIA
McManus (see page 65) provided a litany of benefits that could accrue 
to the development and use of these new pest control technologies. 
Biotechnology can be used to develop new pesticides that are “biora- 
tional" and contribute to environmental sustainability—because they 
may be less toxic to people and other nontarget organisms; kinder and 
gentler to our environment in general. They may also contribute to so-
cial and economic sustainability—because they may be less energy in-
tensive, less costly, and because they may permit farmers to begin 
reducing purchased inputs.
There is indeed great promise. There are many in the business and 
academic worlds who emphasize that promise. That emphasis on pro-
mise is characteristic not just of approaches to biopesticides, but to 
biotechnology in general.
That emphasis is seen in crop biotechnology—for example, a North- 
rup King advertisement shows wheat growing next to the Egyptian 
pyramids with the question “Could the world's deserts be made to 
bloom again?" The apotheosis of this approach is an advertisement 
from Monsanto showing a corn plant growing in barren desert with 
the slogan “Will it take a miracle to solve the world’s hunger prob-
lems?” The implication of the advertisements are that biotechnology is 
miraculous; permitting the growth of wheat and corn even in the de-
sert. More than this, the advertisements suggest that biotechnology is 
a miraculous solution to world hunger.
The advertisement by Monsanto is disingenuous in at least three 
important ways. First, it presents a goal that no one seriously intends 
to pursue: growing corn in a barren desert. Second, it implies that there
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is a technical solution to the problem of world hunger, a problem that 
is as much or more sociopolitical than technological. And third, it uses 
the miraculous and metaphysical as an explanation.
Monsanto is guilty of the very hyperbole it criticizes in those who 
question the way biotechnology is being developed. The invocation of 
technological utopia is no less hyperbolic, no less an exaggeration, 
than invocations of technological apocalypse. And there is actually a 
good deal more of the former than the latter.
This innovation of the apparently magical character of biotechnol-
ogy is again apparent in an advertisement from Pioneer Hi-Bred Inter-
national depicting a medieval alchemist, and containing the slogan 
“Biotechnology, science or alchemy? Biotechnology is, of course, sci-
ence. But why not the alchemical analogy; DNA as the new Philoso-
pher’s Stone, capable of changing base life to gold, to products to pro-
fits? Companies naturally have an interest in emphasizing the promise 
and minimizing the possible problems of a technology because they 
expect to make money. The technological imperative—legitimated 
with reference to technological utopianism—often has a financial im-
perative behind it.
PROBLEMS
The public has heard this technological utopianism before from bu-
siness, academics, the government, and from the press. There is reason 
to distrust technological utopianism. There is a real problem of what 
to do with nuclear and toxic chemical waste. Now newspapers carry 
headlines, such as “Bomb site cleanup is put at billions”. But in 1959 
the Atomic Energy Commission was saying “Waste problems have pro-
ved completely manageable...” Currently there is worry about toxic 
waste dumps and their leakage. But only a few years ago there were ad-
vertisements such as Monsanto’s, “Without chemicals millions more 
would go hungry”. And this from the same company now engaged in 
the development of biological pesticides.
How is the public to respond to the assertion that biological pesti-
cides are the solution and that deliberate release of such biorational 
organisms—miraculous though they may be—is entirely safe and be-
nign? Caution is needed, but note that caution does not mean rejec-
tion. The criticism is of the way biotechnology is being developed, not 
a criticism of biotechnology per se.
Biopesticides
This suggestion of caution is reinforced by the caution of others. A 
recent report titled, “Ecologists wary about environmental releases" 
from a committee of prominent ecologists (nearly 100 reviewed the 
paper) published in Ecology, challenges arguments put forth by those 
in industry and academic circles who would like to see faster develop-
ment and commercialization of genetically engineered biological 
pesticides.
Here is a fundamental problem. Individuals are not involved in the 
development of these technologies. Yet they will certainly affect 
individuals directly or indirectly. Should one embrace what appears to 
be great potentials in biotechnology, when one is uncertain as to the 
balance of costs and benefits. If individuals not involved in the process, 
how can they make an informed decision on issues? Or, if someone 
who is trusted or who has been designated as the public’s representa-
tive is not involved, how can the public decide?
Out of this problem arises a second problem. Technologies have 
differential effects on people—some win, some lose. Not only are there 
both costs and benefits, those costs and benefits are borne in different 
proportions by different social groups. An example is the well-known 
case of the mechanical tomato harvester, whatever the level of gains 
elsewhere in society, those who lost their jobs suffered substantial 
costs. The next gains to society may be positive, but what are the 
ethical implications of excluding from the technology development 
process those who are actually damaged?
ECONOMIC DEMOCRACY
The central social and economic issue in the development of biopesti-
cides—indeed, in the development of biotechnology globally—is the 
question of economic democracy. Citizens of the United States enjoy 
political democracy—they can vote, and thereby influence political 
decision making. More than that, they can belong to a political party 
and by being involved in party activities can help shape party policies 
and objectives. Political democracy means the right to actively parti-
cipate in political institutions; not just to vote yes or no on a candi-
date, but to help select the candidate to run for office.
There is no parallel institutional structure for participation in eco-
nomic decision-making. There is not the right—directly or indirect-
ly—to participate in decision making at Monsanto or Eli Lilly or 
Chrysler or General Foods. It might be argued that economic democ-
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racy exists inasmuch as there is a “vote” on a new technology by deci-
ding to purchase it or not. But this is a degraded sort of economic de-
mocracy parallel to Soviet political democracy in which a candidate is 
presented and citizens vote yes or no. Even the Soviets are moving 
away from that model now.
Full economic democracy is not a feature of the American economy 
at this time. It should be. The fundamental social and ethical task to be 
undertaken in regard to the new biotechnologies is the development of 
institutions to provide full economic democracy—institutions that 
would allow for participation in the development of new technologies 
by a broad range of social interests. Participation in the direction of the 
research and development process is needed.
How? Through what mechanisms? At what levels? By what 
groups? There are few people looking for such mechanisms. There is no 
doubt that it will be difficult. But the point is to make a reasonable be-
ginning because broader social participation in technological develop-
ment is both ethically appropriate and socially rational.
Broader participation is ethically appropriate because those who 
stand to be affected by an economic decision should have a right to par-
ticipate in that decision. The emphasis is on the word “participate”. 
This does not mean “veto”.
Broader participation is ethically appropriate because the effects of 
a new technology are not always predictable. If they cannot be predic-
ted, and if there are going to be unforeseen losses for some, then collec-
tive responsibility is needed for important decisions.
Broader participation is socially rational because if there are formal 
institutional mechanisms for ensuring popular participation, there is a 
provision for collective responsibility and therefore for conflict reduc-
tion. If there is a problem, it is a community problem.
Broader participation is socially rational because enlarged participa-
tion will bring useful additions of information to the development of 
technologies. Lay people have experience and knowledge of a problem 
that experts cannot duplicate. As described in an article titled, “Scien-
tists at the source: farm families are ‘adopting’ agriculture biotechno-
logists”, one biotechnology company is already taking farmers’ indi-
genous knowledge seriously. What farmers know about the produc-
tion process or what patients know about their disease can be applied 
to the development of new technologies.
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Broader participation is socially rational because debate over the 
desirability of competing technological directions highlights the pos-
sibility of generating options. It is socially rational to maintain a diver-
sity of possible technological paths. Why is solar energy not pursued? 
Why are insights not being gleaned from Amish agriculture? When 
narrow interests predominate in setting technological trajectories, it 
must be asked what are the opportunity costs of taking that path, 
what may be the lost alternatives, the foregone options?
Robert Goodman, (see paper page 52) pointed out that farmers have 
a very short range of attention when it comes to their profitability.
The same is true of corporations. There may be good, ethical people in 
companies, but they must sell technologies for profit. If private corpo-
rations are the only ones developing new technologies, to what extent 
does the need to make a profit drive them down one particular techno-
logical path as opposed to another? AH alternatives must be considered 
including those technologies that are socially useful, but not privately 
profitable.
Public institutions, especially Land Grant Universities (LGUs) are 
in a position to pursue these alternatives. They will be pivotal institu-
tions for generating a participatory trajectory. If any measure of eco-
nomic democracy is to be achieved in agricultural colleges, agriculture 
will have to play a leading role. But who are these institutions serving? 
There has been criticism at least since the 1970s suggesting that agri-
business is the principal social group served by the LGUs. Agribusiness 
is already and has long been participating in the shaping of public re-
search agendas. While the LGUs are enlarging participation in agenda 
setting, private companies are expanding their already dominant role.
The increasing penetration of universities by industry is a general 
tendency within higher education at the moment, especially in the 
area of bioscience. During the last ten years a wide range of contractual 
and non-contractual arrangements have been established between 
universities and private businesses in the field of biotechnology. Com-
panies have made their needs known. Monsanto does not provide $62 
million to Washington University without expecting something in 
return. What companies get are a wide range of benefits for their dol-
lars; influence over research agendas, patent rights, licensing rights, 
early looks at new technologies, and a window on university techni-
ques. The result is the “commodification of the university".
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Universities are becoming quite literally marketplaces for knowl-
edge. And as universities become marketplaces, they respond to those 
who have the deepest pockets. There is plenty of demand for lots of 
different research out there in society, as economists, would point out, 
it is “effective demand”—that is, demand backed by dollars—that gets 
a response. While universities are certainly not ivory towers and never 
have been, should they not at least be semi-autonomous from the do-
minant economic powers? If technological options are going to be esta-
blished and maintained, then the continued penetration of universities 
by narrow economic interests cannot be permitted.
A related problem that has accompanied the commodification of 
the university is the overemphasis on biotechnology and an underem-
phasis on other areas of biology. An advertisement from United Agri-
seeds, now subsidiary, shows a corn breeder covered in cobwebs, and 
states, “Some plant breeders are more patient than ours at United 
Agriseeds”, saying in essence that classical plant breeders will not be 
needed anymore because gene transfers will all be done by genetic 
engineering. This advertisement is a social indicator of the funding and 
employment shifts that are underway. Already biotechnology is 
favored in both research support and when hiring at USDA and in col-
leges of agriculture.
It is not that research support should not grow for biotechnology, 
but rather that other areas should not be slighted in the process. This is 
crucial in the area of biopesticides. If agroecology and sustainable agri-
culture are to be seriously pursued, then money will have to be directed 
towards ecology, which has been and continues to be appallingly un-
derfunded.
Lastly, a social and ethical issue that is too little addressed is the to-
tal federal research and development budget. The allocation to ecology 
and molecular biology has been relatively limited. In 1987, 70 percent 
of federal research and development expenditures went to defense. For 
every dollar that went into agricultural research, forty dollars went to 
defense. This is ethically indefensible and socially irrational. The de-
fense budget is an agricultural and sustainable agricultural issue. If the 
nation is going to move towards a sustainable agriculture, the resour-
ces must be made available to it.
Biopesticides
